Data: Bitcoin Spot ETF Net Inflow of $1.81 Billion Last Week, Continuing Three Weeks of Net Inflows
According to ChainCatcher, based on SoSoValue data, Bitcoin spot ETFs had a net inflow of $1.81 billion during the trading days of last week (April 28 to May 2, Eastern Time).
The Bitcoin spot ETF with the highest net inflow last week was Blackrock's Bitcoin ETF IBIT, with a weekly net inflow of $2.48 billion. Currently, IBIT's total historical net inflow has reached $43.68 billion. Following that is Grayscale's Bitcoin Mini Trust ETF BTC, with a weekly net inflow of $41.92 million, and its total historical net inflow has reached $1.31 billion.
The Bitcoin spot ETF with the highest net outflow last week was Ark Invest and 21Shares' Bitcoin ETF ARKB, with a weekly net outflow of $458 million. After setting a historical high for weekly net inflow, last week's net outflow also set a historical high, with ARKB's total historical net inflow now at $2.65 billion.
As of the time of writing, the total net asset value of Bitcoin spot ETFs is $113.15 billion, with an ETF net asset ratio (market value compared to the total market value of Bitcoin) of 5.87%, and the historical cumulative net inflow has reached $40.24 billion.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Just about three months after listing, two SK Hynix leveraged ETFs are set to be delisted in the United States.
Tradr ETFs announced that its two leveraged products linked to SK Hynix ADRs will be liquidated and delisted around November 12, with one being long and the other short. Despite only being listed for a few months, their combined scale has shrunk to about $1.3 million, down more than 60% from their peak. SK Hynix's Seoul stock price has fallen 56% from its high, similar products in the industry are generally under pressure, and South Korea has also further tightened regulations on leveraged products.
WTI Price Forecast: Slides further below $100.50; bullish potential seems intact
A $5 billion single-product emerges? JPMorgan maintains a "Neutral" rating on Amgen (AMGN.US): A good drug doesn't necessarily mean a good buying opportunity.
Amgen's Imdelltra has maintained data with an HR of 0.42, nearly doubling survival time. Morgan Stanley estimates that it will become a single product with annual sales of around 5 billions USD. However, they maintain a Neutral rating and a target price of 350 USD.
Crypto prices
More
